According to media reports, the State Drug Administration has recently reviewed and approved the registration application for the innovative product of the “software for fundus image-assisted diagnosis of chronic glaucoma-like optic neuropathy” developed by Tencent Healthcare (Shenzhen) Co., Ltd. The approval of AI-assisted diagnosis of glaucoma marks that Tencent has become the first Internet technology company in China to be approved for innovative medical devices.
CNMO has learned that Tencent Miying’s “fundus image-aided diagnosis software for chronic glaucoma-like optic neuropathy” was officially approved for marketing after passing the special review process for innovative medical devices. This set of products mainly uses deep learning artificial intelligence algorithms, which can provide clinical auxiliary triage suggestions and give hints about whether there is suspected chronic glaucoma-like optic neuropathy. Moreover, it also provides a quality control method for fundus camera imaging, which can automatically identify common fundus image quality problems in clinical, such as non-fundus images, and improve the accuracy and confidence of auxiliary diagnosis.
Tencent Miying provides doctors with advice on glaucoma diagnosis
Qian Tianyi, general manager of Tencent Miying, said that with the help of digital technologies such as cloud computing and 5G network, Tencent Miying’s diagnostic software is expected to form a new model of remote screening based on the Internet and expand the coverage of glaucoma screening.